Coherus BioSciences Management to Present at BofA Securities 2020 Health Care Conference

Rhea-AI Summary

Coherus BioSciences (CHRS) will present at the BofA Securities 2020 Health Care Conference on May 14, 2020, at 1:00 p.m. ET. The presentation will be streamed live on their investor page. Coherus is a biosimilar leader focused on developing therapeutics for chronic diseases while enhancing patient access and reducing costs. The company markets UDENYCA® in the U.S. and is advancing several biosimilars, including CHS-1420, targeting Humira® and others. Visit https://investors.coherus.com for more details.

REDWOOD CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will make a virtual presentation at BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 1:00 p.m. ET.

The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at https://investors.coherus.com.

About Coherus BioSciences, Inc.

Coherus is a leading biosimilar company that develops and commercializes its own high-quality therapeutics as well as those of others seeking capable access to the United States market. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus commercializes UDENYCA® (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA® in the European Union. Coherus is advancing late-stage clinical products CHS-1420, a Humira® (adalimumab) biosimilar, Bioeq’s Lucentis® (ranibizumab) biosimilar and Innovent’s Avastin® (bevacizumab) biosimilar towards commercialization, and early-stage clinical products, CHS-2020, an Eylea® (aflibercept) biosimilar, and CHS-131, a small molecule for nonalcoholic steatohepatitis (NASH) and multiple sclerosis. For additional information, please visit www.coherus.com.

Contact

David S. Arrington
Investor Relations & Corporate Affairs
Coherus BioSciences, Inc.
darrington@coherus.com
+1 (650) 395-0196

FAQ

When is Coherus BioSciences' presentation at the BofA Securities 2020 Health Care Conference?

Coherus BioSciences will present on May 14, 2020, at 1:00 p.m. ET.

How can I listen to the Coherus BioSciences conference presentation?

The audio of the presentation will be available on the Coherus investor page at https://investors.coherus.com.

What are the key products Coherus BioSciences is developing?

Coherus is developing several biosimilars, including CHS-1420 for Humira®, and others for Lucentis® and Avastin®.

What is the significance of biosimilars according to Coherus BioSciences?

Biosimilars aim to replace existing biologics, potentially lowering costs and expanding patient access to treatments.

What is UDENYCA® and its market status?

UDENYCA® (pegfilgrastim-cbqv) is marketed by Coherus in the U.S. and has also received regulatory approval in the European Union.